Search Result

Results for "

LDH-A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Lactate Dehydrogenase (30) Apoptosis (10) Bacterial (1) PDK-1 (2) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (5) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (30) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (3)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Lactate Dehydrogenase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W013032A

Oxamic acid sodium Maximum Cited Publications 58 Publications Verification Sodium oxamate	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-100681

GSK2837808A 40+ Cited Publications	Lactate Dehydrogenase	Cancer
GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC₅₀s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.

HY-16214

FX-11 25+ Cited Publications LDHA Inhibitor FX11	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS)	Cancer
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .

HY-100742A

(R)-GNE-140 15+ Cited Publications	Lactate Dehydrogenase	Cancer
(R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC₅₀s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.

HY-W013032

Oxamic acid 55+ Cited Publications Oxamidic acid	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-W040118

Galloflavin 10+ Cited Publications	Lactate Dehydrogenase	Cancer
Galloflavin is a potent lactate dehydrogenase *(LDH)* inhibitor. The calculated K_is for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .

HY-111108

LDH-IN-1 2 Publications Verification	Lactate Dehydrogenase	Cancer
LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase *(LDH)* with IC₅₀s of 32 and 27 nM for LDHA and LDHB, respectively.

HY-100742

GNE-140 racemate 5+ Cited Publications	Lactate Dehydrogenase	Cancer
GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .

HY-18968

AZ-33 1 Publications Verification LDHA-IN-4	Lactate Dehydrogenase	Cancer
AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC₅₀ of 0.5 μM and a K_d of 0.093 μM .

HY-124309

NHI-2	Lactate Dehydrogenase Apoptosis	Cancer
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC₅₀ of 14.7 µM. NHI-2 shows selective for *LDHA* over LDHB (IC₅₀ = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .

HY-152261

MS6105	PROTACs	Cancer
MS6105 is an *LDH* protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity . MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139319

LDHA-IN-3 2 Publications Verification	Lactate Dehydrogenase	Cancer
LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC₅₀=145.2 nM). LDHA-IN-3 can be used for the research of cancer .

HY-100742B

(S)-GNE-140	Lactate Dehydrogenase	Cancer
(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).

HY-156683

CHK-336	Lactate Dehydrogenase	Metabolic Disease
CHK-336 (Example 1) is an orally active *LDHA* inhibitor (IC₅₀<1 nM). CHK-336 inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .

HY-176798

NCI-006	Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis	Cancer
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC₅₀ = 0.06 μM; LDHB IC₅₀ = 0.03 μM). NCI-006 inhibits intratumoral *LDH* activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .

HY-RS07571

LDHA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LDHA Human Pre-designed siRNA Set A contains three designed siRNAs for LDHA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LDHA Human Pre-designed siRNA Set A LDHA Human Pre-designed siRNA Set A

HY-175230

ZG-2492	Lactate Dehydrogenase Apoptosis	Cancer
ZG-2492 is an orally active *LDHA* inhibitor with an IC₅₀ of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .

HY-115875

LDHA-IN-5	Lactate Dehydrogenase	Metabolic Disease
LDHA-IN-5 is a novel, potent, dual *GO/LDHA* inhibitor for primary hyperoxaluria.

HY-178461

LDHA-IN-10	Lactate Dehydrogenase	Cancer
LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC₅₀ value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .

HY-147361

LDCA	Apoptosis Lactate Dehydrogenase	Cancer
LDCA is a dual-hit metabolic modulator and inhibits *LDH-A* enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .

HY-162627

LDHA-IN-6	Lactate Dehydrogenase	Cancer
LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC₅₀ of 46 nM. LDHA-IN-6 has antitumor activity .

HY-169060

LDHA-IN-8	Lactate Dehydrogenase	Cancer
LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits *LDHA* catalysis of pyruvate in a dose-dependent manner (EC₅₀ value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .

HY-168733

LDHA-IN-9	Lactate Dehydrogenase Apoptosis	Cancer
LDHA-IN-9 (Compound 1g) is an inhibitor for *LDH-A* with an IC₅₀ of 25 nM. LDHA-IN-9 inhibits the proliferation of DLD-1 cell (GI₅₀ of 27 μM) through apoptosis induction. LDHA-IN-9 exhibits antitumor activity in mouse model without significant toxicity (25 mg/kg) .

HY-162629

LDHA-IN-7	Lactate Dehydrogenase	Cancer
LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC₅₀s of 72 nM and 1.2 Μm, respectively .

HY-146977

LDHA/PDKs-IN-1	PDK-1	Cancer
LDHA/PDKs-IN-1 (compound 20e) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 0.8 and 0.15 μM, respectively. LDHA/PDKs-IN-1 reduces A549 cell proliferation with an EC₅₀ of 13.2 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-1 has the potential for the research of cancer diseases .

HY-146978

LDHA/PDKs-IN-2	PDK-1	Cancer
LDHA/PDKs-IN-2 (compound 20k) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 1.6 and 0.7 μM, respectively. LDHA/PDKs-IN-2 reduces A549 cell proliferation with an EC₅₀ of 15.7 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-2 has the potential for the research of cancer diseases .

HY-RS16503

Ldha Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ldha Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldha gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ldha Mouse Pre-designed siRNA Set A Ldha Mouse Pre-designed siRNA Set A

HY-16964

LDHA-IN-1	Lactate Dehydrogenase	Cancer
LDHA-IN-1 (Compound 1j) is a selective, competitive *LDH-A* inhibitor, with K_i values of 8.9 μM (NADH assay) and 4.7 μM (Pyruvate assay) against hLDH-A. LDHA-IN-1 inhibits cancer cell proliferation under hypoxic conditions. LDHA-IN-1 can be used in the research of ovarian cancer, colorectal cancer, mesothelioma and pancreatic cancer .

HY-W013032R

Oxamic acid (Standard) Oxamidic acid (Standard)	Reference Standards Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].

HY-180992

*Dual GO/LDHA-IN-1*	Lactate Dehydrogenase	Metabolic Disease
Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1 .

HY-RS22935

Ldha Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ldha Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldha gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ldha Rat Pre-designed siRNA Set A Ldha Rat Pre-designed siRNA Set A

HY-100742AR

(R)-GNE-140 (Standard)	Lactate Dehydrogenase Reference Standards	Cancer
(R)-GNE-140 (Standard) is the analytical standard of (R)-GNE-140 (HY-100742A). This product is intended for research and analytical applications. (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.

HY-100681R

GSK2837808A (Standard)	Lactate Dehydrogenase Reference Standards	Cancer
GSK2837808A (Standard) is the analytical standard of GSK2837808A (HY-100681). This product is intended for research and analytical applications. GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.

HY-100742BR

(S)-GNE-140 (Standard)	Lactate Dehydrogenase Reference Standards	Cancer
(S)-GNE-140 (Standard) is the analytical standard of (S)-GNE-140 (HY-100742B). This product is intended for research and analytical applications. (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).

HY-100742R

GNE-140 racemate (Standard)	Lactate Dehydrogenase Reference Standards	Cancer
GNE-140 (racemate) (Standard) is the analytical standard of GNE-140 (racemate) (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .

HY-118241

GNE-140	Lactate Dehydrogenase Bacterial Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Infection Inflammation/Immunology Cancer
GNE-140 is an orally active and selective inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC₅₀ values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. GNE-140 attenuates cardiac hypertrophy, alleviates PM_2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression, regulates metabolites of glycolysis and the pentose phosphate pathway, reduces glucose uptake, increases ROS, and induces cancer cell apoptosis. GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .

Cat. No.	Product Name

HY-L249

Lactylation Compound Library	5,860 compounds
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis. MCE has assembled a collection of 5,860 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Lactylation Compound Library

5,860 compounds

Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.

MCE has assembled a collection of 5,860 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W013032

Oxamic acid 55+ Cited Publications Oxamidic acid	Microorganisms Source Classification	Lactate Dehydrogenase Apoptosis
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-W013032R

Oxamic acid (Standard) Oxamidic acid (Standard)	Microorganisms Source Classification	Reference Standards Lactate Dehydrogenase Apoptosis
Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].

Species:	Human (1) Rat (1) Mouse (2)
Tag:	His (4)
Source:	HEK293 (1) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P73271

	LDHA Protein, Rat (His) L-lactate dehydrogenase A chain; LDH-A; LDH-M; LDHa; LDH-1	Rat	E. coli
	The LDHA protein facilitates the simultaneous and stereospecific interconversion of pyruvate and lactate, accompanied by the concomitant exchange of NADH and NAD(+).LDHA Protein, Rat (His) is the recombinant rat-derived LDHA protein, expressed by E.coli , with N-His labeled tag.

HY-P73270

	LDHA Protein, Mouse (His) L-lactate dehydrogenase A chain; LDH-A; LDH-M; LDHa; LDH-1	Mouse	E. coli
	LDHA protein catalyzes the simultaneous and stereospecific interconversion of pyruvate and lactate, accompanied by the reciprocal interconversion of NADH and NAD(+).LDHA Protein, Mouse (His) is the recombinant mouse-derived LDHA protein, expressed by E.coli , with N-His labeled tag.

HY-P70225

	LDHA Protein, Human (His) rHuL-lactate dehydrogenase A chain/LDH-A, His; L-Lactate Dehydrogenase A Chain; LDH-A; Cell Proliferation-Inducing Gene 19 Protein; LDH Muscle Subunit; LDH-M; Renal Carcinoma Antigen NY-REN-59; LDHA	Human	E. coli
	LDHA protein catalyzes the stereospecific interconversion of pyruvate and lactate, concomitantly exchanging NADH and NAD(+). LDHA Protein, Human (His) is the recombinant human-derived LDHA protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70259

	LDHA Protein, Mouse (HEK293, His) rMuL-lactate dehydrogenase, His; LDHA; LDH1; L-lactate dehydrogenase	Mouse	HEK293
	LDHA protein catalyzes the simultaneous and stereospecific interconversion of pyruvate and lactate, accompanied by the reciprocal interconversion of NADH and NAD(+).LDHA Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDHA protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Rabbit (4)
Reactivity:	Human (4) Rat (3) Mouse (2)
Application:	IHC-P (4) ICC/IF (4) IP (4) IHC-F (2) WB (4) FC (1) ELISA (1)
Isotype:	IgG (4)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86602

	Lactate Dehydrogenase Antibody (YA6294) LDHA; PIG19; LDHB; LDHC; LDH3; LDHX; L-lactate dehydrogenase A chain; LDH-A; Cell proliferation-inducing gene 19 protein; LDH muscle subunit; LDH-M; Renal carcinoma antigen NY-REN-59; L-lactate dehydrogenase B chain; LDH-B; LDH heart subunit; LDH-H; Renal carcinoma antigen NY-REN-46; L-lactate dehydrogenase C chain; LDH-C; Cancer/testis antigen 32; CT32; LDH testis subunit; LDH-X;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Lactate Dehydrogenase Antibody (YA6294) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lactate Dehydrogenase.

HY-P80422

	Lactate Dehydrogenase Antibody (YA316)	WB, ICC/IF, IHC-P, FC, IP	Human, Mouse
	Lactate Dehydrogenase Antibody (YA316) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lactate Dehydrogenase.

HY-P80738

	Lactate Dehydrogenase A Antibody (YA317) LDHA; LDH-M; LDH1; PIG19; GSD11; TRG5; Proliferation inducing gene 19	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Rat
	Lactate Dehydrogenase A Antibody (YA317) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lactate Dehydrogenase A.

HY-P80738A

	Lactate Dehydrogenase A Antibody (YA317)(PBS only) LDHA; LDH-M; LDH1; PIG19; GSD11; TRG5; Proliferation inducing gene 19	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Rat
	Lactate Dehydrogenase A Antibody (YA317) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lactate Dehydrogenase A.